Skip Navigation Links   >   Home   >   News & Media
22 August 2019

Cannabinoids in medicine Part 1: Cancer

In the first of a series of five articles, Oxford Cannabinoid Technologies will discuss their expertise on the medicinal use of cannabis derivatives.

This first piece will focus on the use of cannabinoids to treat cancer. The term ‘cannabinoid’ originally referred to a group of compounds found in the species of the cannabis plant known as Cannabis sativa.(1) Following the development of synthetic derivatives of cannabinoids and the discovery of natural endocannabinoids, the term ‘phytocannabinoid’ was given to cannabinoids obtained from cannabis plants.(2)

The best-known of these phytocannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD) and two well-known cannabinoid receptors in the brain are CB1 and CB2. The CB1 receptor binds with THC and is thereby responsible for THC’s psychotropic effects. Most if not all phytocannabinoids, however, act on more receptors than just these – the study of these compounds is, therefore, highly complex and their potential to treat a wide range of diseases is highly significant.

The potential of cannabinoids to alleviate the symptoms of cancer and even treat its underlying causes has been discussed since pre-clinical research papers in the early 1970s demonstrated that the growth of lung tumours in mice could be slowed by THC and other cannabinoids.(3) While the ability of cannabinoids to alleviate the symptoms of cancer is widely accepted, pre-clinical studies suggest that cannabinoids may be effective in the actual treatment of multiple cancer types (for instance glioblastoma multiforme((4)) and prostate cancer((5)). Some studies have also affirmed that cannabinoids have a protective effect against certain types of tumours. Others suggest that cannabinoids can inhibit proliferation, metastasis and migration of cancer cells and even induce their death.

Read the full article here

    All News

    • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

      OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

      28 July 2020 OCT Press Release
    • Cannabinoids in medicine part 5: Treating COVID-19

      17 June 2020 Open Access Government
    • Why the Government should continue to invest in Life Sciences post COVID-19

      Why the government should continue to invest in Life Sciences post COVID-19

      01 June 2020 OCT blog - John Lucas, COO
    • OCT researchers publish new study examining genes involved in treating neuropathic pain

      19 April 2020 OCT Press Release
    • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

      03 April 2020 OCT Press Release
    • Cannabinoids in medicine part 4: Epilepsy

      30 March 2020 Open Access Government
    • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

      07 January 2020 Open Access Government
    • Cannabinoids in medicine Part 2: Pain

      11 October 2019 Open Access Government
    • Cannabinoids in medicine Part 1: Cancer

      22 August 2019 Open Access Government
    • An interview with Neil Mahapatra

      08 January 2019 The Times Magazine
    • High life: the start-up hoping to unlock the secrets of medical cannabis

      09 August 2018 Evening Standard
    • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

      28 June 2018 OCT Press Release
    • Embracing the medical potential of cannabinoids

      01 June 2017 The Medicine Maker
    • Smashing the stigma with science

      01 June 2017 The Medicine Maker
    • Oxford University launches £10m research project into medical marijuana

      16 March 2017 Evening Standard
    • Oxford University to launch study on medical benefits of marijuana

      16 March 2017 The Telegraph
    • Oxford University to launch multimillion-dollar medical marijuana research program

      16 March 2017 CNBC
    • Oxford University launches £10m marijuana research programme

      16 March 2017 BBC
    • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

      15 March 2017 OCT Press Release